Co-trimaxazole therapy: place and prospects.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects; D001437:Bacteriuria / Q000188:drug therapy; D004338:Drug Combinations; D004352:Drug Resistance, Microbial; D004357:Drug Synergism; D004926:Escherichia coli / Q000201:enzymology; D005333:Fetus / Q000201:enzymology; D005492:Folic Acid / Q000627:therapeutic use; D005493:Folic Acid Antagonists / Q000627:therapeutic use*; D006801:Humans; D051379:Mice; D008826:Microbial Sensitivity Tests; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D011743:Pyrimidines / Q000627:therapeutic use*; D012008:Recurrence; D012141:Respiratory Tract Infections / Q000188:drug therapy; D013420:Sulfamethoxazole / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013936:Thymidine / Q000378:metabolism; D014295:Trimethoprim / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D005493:Folic Acid Antagonists; D011743:Pyrimidines; D005492:Folic Acid; D014295:Trimethoprim; D013420:Sulfamethoxazole; D013936:Thymidine